.png){kind=icon}
.png){kind=icon}
Return
Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial
.png){kind=icon}
PRE
AI
C
Y
K
X
J
M
L
F
DOI：10.1111/jgh.70554.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Ursodeoxycholic acid (UDCA) is first-line therapy for primary biliary cholangitis (PBC), evidence for dose reduction after biochemical remission remains limited. This study aimed to evaluate the feasibility and safety of UDCA reduction in PBC.
Keywords:
cost of illness
drug tapering
primary biliary cholangitis
ursodeoxycholic acid
Journal
IF:
3.4
Papers:
1.0W
Citations:
1.5W
Organization
Cited Papers